<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urovest</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник урологии</journal-title><trans-title-group xml:lang="en"><trans-title>Urology Herald</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2308-6424</issn><publisher><publisher-name>Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2308-6424-2016-0-2-60-83</article-id><article-id custom-type="elpub" pub-id-type="custom">urovest-93</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURES</subject></subj-group></article-categories><title-group><article-title>ОСТРЫЙ И ХРОНИЧЕСКИЙ ПРОСТАТИТ – ЧТО ВАЖНО ДЛЯ ПРАКТИКИ?</article-title><trans-title-group xml:lang="en"><trans-title>AKUTE UND CHRONISCHE PROSTATITIS - WAS IST WICHTIG FÜR DIE PRAXIS?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Набер</surname><given-names>К.Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Naber</surname><given-names>K.G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>94315, Германия, г.Штраубинг, Карл-Бикледер штрассе 44с</p></bio><bio xml:lang="en"><p>94315, Karl-Bickleder-Str. 44c, Straubing</p></bio><email xlink:type="simple">kurt@nabers.de</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Валенсик</surname><given-names>В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vahlensieck</surname><given-names>W.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бад-Наухайм</p></bio><bio xml:lang="en"><p>Bad Nauheim</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вагенленер</surname><given-names>Ф.М.Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Wagenlehner</surname><given-names>F.M.E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гиссен</p></bio><bio xml:lang="en"><p>Giessen</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Технический университет Мюнхена</institution><country>Германия</country></aff><aff xml:lang="en"><institution>Technische Universität München, München</institution><country>Germany</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Специализированная клиника урологии, Курпарк-Клиник</institution><country>Германия</country></aff><aff xml:lang="en"><institution>Fachklinik Urologie, Kurpark-Klinik</institution><country>Germany</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Клиника урологии, детской урологии и андрологии университетского&#13;
госпиталя Гиссена и Марбурга</institution><country>Германия</country></aff><aff xml:lang="en"><institution>Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, Universitätsklinikum Giessen und Marburg</institution><country>Germany</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>20</day><month>06</month><year>2016</year></pub-date><volume>0</volume><issue>2</issue><fpage>60</fpage><lpage>83</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Набер К., Валенсик В., Вагенленер Ф., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Набер К., Валенсик В., Вагенленер Ф.</copyright-holder><copyright-holder xml:lang="en">Naber K., Vahlensieck W., Wagenlehner F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.urovest.ru/jour/article/view/93">https://www.urovest.ru/jour/article/view/93</self-uri><abstract><p>Простатит является частым и комплексным заболеванием. На протяжении последних 40 лет научное познание проходило разные стадии, иногда с успехами, а иногда с заблуждениями. В то время как острый простатит почти всегда соответствует острой бактериальной инфекции, при синдроме хронического простатита причинные возбудители обнаруживаются лишь примерно в 10% случаев. Спектр возбудителей, по сути, соответствует таковому при осложненных инфекциях мочевых путей с присутствием преимущественно грамотрицательных возбудителей. Однако в некоторых исследованиях были обнаружены и атипичные возбудители, такие как Chlamydia trachomatis и микоплазмы. В подавляющем большинстве случаев признавалось наличие многофакторных причин. В конце концов, это привело к внедрению фенотипирования симптоматики с мультимодальными программами лечения. Если причиной (одной из причин) заболевания однозначно является инфекция, то, по-прежнему, большое значение придается антибиотикам, прежде всего фторхинолонам. В остальных случаях реализуются мультимодальные стратегии лечения, основанные на монотерапевтических исследованиях на базе доказательной медицины. До сих пор существуют только единичные исследования мультимодальных комбинированных способов лечения, которые, однако, являются чрезвычайно перспективными.</p></abstract><trans-abstract xml:lang="en"><p>Die Prostatitis ist eine häufige und komplexe Erkrankung. Im Verlauf der letzten 40 Jahre haben sich verschiedene Stadien der wissenschaftlichen Wahrnehmung, zum Teil mit Erfolgen und zum Teil mit Irrwegen aufgezeigt. Während die akute Prostatitis fast immer einer akuten bakteriellen Infektion entspricht, finden sich beim chronischen Prostatitissyndrom nur in etwa 10 % der Fälle ursächliche Erreger. Das Erregerspektrum entspricht im Wesentlichen dem von komplizierten Harnwegsinfektionen mit vornehmlich Gram-negativen Erregern. In manchen Studien wurden aber auch atypische Erreger, wie Chlamydia trachomatis und Mykoplasmen gefunden. Bei der überwiegenden Mehrzahl der Fälle werden multifaktorielle Ursachen angenommen. Dies führte schließlich zur Phänotypisierung der Beschwerdesymptomatik mit multimodalen Therapiekonzepten. Bei eindeutig infektiöser (Mit-)Ursache der Beschwerden haben Antibiotika – allen voran Fluorchinolone – nach wie vor einen hohen Stellenwert. Ansonsten erfolgen multimodale Therapiestrategien, die auf Evidenz-basierten monotherapeutischen Studien aufbauen. Bisher liegen nur wenige Studien zu multimodalen Kombinationstherapien vor, die aber durchaus vielversprechend sind.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>острый простатит</kwd><kwd>хронический простатит</kwd><kwd>синдром хронической тазовой боли</kwd></kwd-group><kwd-group xml:lang="en"><kwd>akute Prostatitis</kwd><kwd>chronische Prostatitis</kwd><kwd>Chronisches Schmerzsyndrom im kleinen Becken</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Walz J, Perrotte P, Hutterer G, et al. Impact of chronic prostatitis like symptoms on the quality of life in a large group of men. BJU Int. 2007;100:1307-1311.</mixed-citation><mixed-citation xml:lang="en">Walz J, Perrotte P, Hutterer G, et al. Impact of chronic prostatitis like symptoms on the quality of life in a large group of men. BJU Int. 2007;100:1307-1311.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lee SW1, Liong ML, Yuen KH, Leong WS, Cheah PY, Khan NA, Krieger JN. Adverse impact of sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. Urology. 2008;71:79-84.</mixed-citation><mixed-citation xml:lang="en">Lee SW1, Liong ML, Yuen KH, Leong WS, Cheah PY, Khan NA, Krieger JN. Adverse impact of sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. Urology. 2008;71:79-84.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">j L, Dy K. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: a meta-analysis. World J Urol. 2015 Nov 6. [Epub ahead of print]</mixed-citation><mixed-citation xml:lang="en">j L, Dy K. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: a meta-analysis. World J Urol. 2015 Nov 6. [Epub ahead of print]</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282(3):236-237</mixed-citation><mixed-citation xml:lang="en">Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282 (3):236-237</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wagenlehner FME, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, Hartung R, Weidner W. The role of inflammation and infection in the pathogenesis of prostate carcinoma. Brit J of Urol Int 2007;100:733-737.</mixed-citation><mixed-citation xml:lang="en">Wagenlehner FME, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, Hartung R, Weidner W. The role of inflammation and infection in the pathogenesis of prostate carcinoma. Brit J of Urol Int 2007;100:733-737.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yoon BI, Kim S, Han DS, Ha US, Lee SJ, Kim HW, Han CH, Cho YH. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother 2012;18:444-50.</mixed-citation><mixed-citation xml:lang="en">Yoon BI, Kim S, Han DS, Ha US, Lee SJ, Kim HW, Han CH, Cho YH. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother 2012;18:444-50.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Schaeffer AJ. Prostatitis: US perspective. Int J Antimicr Agents 1999;11:205-216</mixed-citation><mixed-citation xml:lang="en">Schaeffer AJ. Prostatitis: US perspective. Int J Antimicr Agents 1999;11:205-216 8. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968;5:492-518</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968;5:492-518</mixed-citation><mixed-citation xml:lang="en">Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE, Zeitlin S, O'Leary MP, Pontari MA, Schaeffer AJ, Landis JR, Nyberg L, Kusek JW, Kathleen J. Propert KJ, and the Chronic Prostatitis Collaborative Research Network Study Group. How does the premassage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 2006;176:119-124</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE, Zeitlin S, O'Leary MP, Pontari MA, Schaeffer AJ, Landis JR, Nyberg L, Kusek JW, Kathleen J. Propert KJ, and the Chronic Prostatitis Collaborative Research Network Study Group. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 2006;176:119-124</mixed-citation><mixed-citation xml:lang="en">Weidner W, Jantos C, Schiefer HG, Haidl G, Friedrich JJ. Semen parameters in men with and without proven chronic prostatitis. Arch Androl 1991;26:173-183</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Weidner W, Jantos C, Schiefer HG, Haidl G, Friedrich JJ. Semen parameters in men with and without proven chronic prostatitis. Arch Androl 1991;26:173-183</mixed-citation><mixed-citation xml:lang="en">Mazzoli S, Cai T, Rupealta V, Gavazzi A, Pagliai RC, Mondaini N, Bartoletti R. Interleukin 8 and anti-Chlamydia trachomatis mucosal IgA as urogenital immunologic markers in patients with C. trachomatis prostatic infection. Eur Urol 2007;51:1385–1393</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzoli S, Cai T, Rupealta V, Gavazzi A, Pagliai RC, Mondaini N, Bartoletti R. Interleukin 8 and anti-Chlamydia trachomatis mucosal IgA as urogenital immunologic markers in patients with C. trachomatis prostatic infection. Eur Urol 2007;51:1385–1393</mixed-citation><mixed-citation xml:lang="en">Naber K. Antibiotic treatment of chronic bacterial prostatitis. In: Nickel J (ed) Textbook of prostatitis. ISIS medical media Ltd, Oxford. 1999;285-292</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Naber K. Antibiotic treatment of chronic bacterial prostatitis. In: Nickel J (ed) Textbook of prostatitis. ISIS medical media Ltd, Oxford. 1999;285-292</mixed-citation><mixed-citation xml:lang="en">Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev. 2013 Aug 12;8:CD009071</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev. 2013 Aug 12;8:CD009071</mixed-citation><mixed-citation xml:lang="en">Wagenlehner FME, Lunz JC, Kees F, Wieland W, Naber KG. Serum und prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. J Chem 2006;18:485-489</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wagenlehner FME, Lunz JC, Kees F, Wieland W, Naber KG. Serum und prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. J Chem 2006;18:485-489</mixed-citation><mixed-citation xml:lang="en">Wagenlehner FME, Kees F, Weidner W, Wagenlehner C, Naber KG. Concentrations of moxifloxacin in plasma and urine and penetration into prostatic fluid and ejaculate, following single oral administration of 400mg to healthy volunteers. Int J Antimcr Agents 2008;31:21-26</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wagenlehner FME, Kees F, Weidner W, Wagenlehner C, Naber KG. Concentrations of moxifloxacin in plasma and urine and penetration into prostatic fluid and ejaculate, following single oral administration of 400mg to healthy volunteers. Int J Antimcr Agents 2008;31:21-26</mixed-citation><mixed-citation xml:lang="en">Perletti G, Wagenlehner FME, Naber KG, Magri V. Enhanced distribution of fourth-generation fluoroquinolones in prostatic tissue. Int J Antimicr Agents 2009;33:206-</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Perletti G, Wagenlehner FME, Naber KG, Magri V. Enhanced distribution of fourth-generation fluoroquinolones in prostatic tissue. Int J Antimicr Agents 2009;33:206-210</mixed-citation><mixed-citation xml:lang="en">Perletti G, Wagenlehner FME, Naber KG, Magri V. Enhanced distribution of fourth-generation fluoroquinolones in prostatic tissue. Int J Antimicr Agents 2009;33:206-210</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Barbalias GA, Nikiforidis G, Liatsikos EN. α-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998;159:883-887</mixed-citation><mixed-citation xml:lang="en">Barbalias GA, Nikiforidis G, Liatsikos EN. α-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998;159:883-887</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Magri V, Montanari E, Skerk V, Markotic A, Marras E, Restelli A, Naber KG, Perletti G. Fluoroquinolone–macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian J Andrology 2011;13:819-827</mixed-citation><mixed-citation xml:lang="en">Magri V, Montanari E, Skerk V, Markotic A, Marras E, Restelli A, Naber KG, Perletti G. Fluoroquinolone–macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian J Andrology 2011;13:819-827</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kolumbić-Lakos A, Skerk V, Maleković G, Dujnić-Spoljarević T, Kovacic D, Pasini M, Markotić A, Magri V, Perletti G. A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study. J Chemother. 2011;23(6):350-3</mixed-citation><mixed-citation xml:lang="en">Kolumbić-Lakos A, Skerk V, Maleković G, Dujnić-Spoljarević T, Kovacic D, Pasini M, Markotić A, Magri V, Perletti G. A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study. J Chemother. 2011;23 (6):350-3</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Baert L, Herremans D. Radical transurethral prostatectomy for chronic bacterial prostatitis. In: Weidner W, Madsen PO, Schiefer HG (eds.) Prostatitis. Etiopathology, Diagnosis and Therapy. Springer, Berlin, Heidelberg, New York etc. 1994;197-205</mixed-citation><mixed-citation xml:lang="en">Baert L, Herremans D. Radical transurethral prostatectomy for chronic bacterial prostatitis. In: Weidner W, Madsen PO, Schiefer HG (eds. ) Prostatitis. Etiopathology, Diagnosis and Therapy. Springer, Berlin, Heidelberg, New York etc. 1994;197-205</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">de la Rosette JJ, Hubregtse MR, Meuleman EJ, Stolk-Engelaar MV, Debruyne FM. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993;41:301-307</mixed-citation><mixed-citation xml:lang="en">de la Rosette JJ, Hubregtse MR, Meuleman EJ, Stolk-Engelaar MV, Debruyne FM. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993;41:301-307</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hochreiter W, Ludwig M, Weidner W et al. National Institutes of Health Chronic Prostatitis Symptom Index. Urologe [A] 2001;40:16–17</mixed-citation><mixed-citation xml:lang="en">Hochreiter W, Ludwig M, Weidner W et al. National Institutes of Health Chronic Prostatitis Symptom Index. Urologe [A] 2001;40:16–17</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">McNaughton Collins M, Pontari MA, O’Leary MP et al. Chronic Prostatitis Collaborative Research Network. Quality of life is impaired in men with chronic prostatitis. J Gen Intern Med 2001;16(10):656-662</mixed-citation><mixed-citation xml:lang="en">McNaughton Collins M, Pontari MA, O’Leary MP et al. Chronic Prostatitis Collaborative Research Network. Quality of life is impaired in men with chronic prostatitis. J Gen Intern Med 2001;16 (10):656-662</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">McNaughton Collins M, MacDonald R, Wilt TJ. Diagnosisand treatment of chronic abacterial prostatitis. Ann Intern Med 2000;133(5):367-381</mixed-citation><mixed-citation xml:lang="en">McNaughton Collins M, MacDonald R, Wilt TJ. Diagnosisand treatment of chronic abacterial prostatitis. Ann Intern Med 2000;133 (5):367-381</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hetrick DC, Ciol MA, Rothman I et al. Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III. J Urol 2003;170(3):828-831</mixed-citation><mixed-citation xml:lang="en">Hetrick DC, Ciol MA, Rothman I et al. Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III. J Urol 2003;170 (3):828-831</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hochreiter WW, Nadler RB, Koch AE et al. Evaluationof the cytokines interleukin 8 and epithelial neutrophilactivating peptide 78 as indicators of inflammation in prostatic secretions. Urology 2000;56(6):1025-1029.</mixed-citation><mixed-citation xml:lang="en">Hochreiter WW, Nadler RB, Koch AE et al. Evaluationof the cytokines interleukin 8 and epithelial neutrophilactivating peptide 78 as indicators of inflammation in prostatic secretions. Urology 2000;56 (6):1025-1029.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Anothaisintawee T, Attia J, Nickel JC, Thammakraisorn S, Numthavaj P, McEvoy M, Thakkinstian A. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 2011;305:78-86</mixed-citation><mixed-citation xml:lang="en">Anothaisintawee T, Attia J, Nickel JC, Thammakraisorn S, Numthavaj P, McEvoy M, Thakkinstian A. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 2011;305:78-86</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009;73:538–542</mixed-citation><mixed-citation xml:lang="en">Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom  severity. Urology 2009;73:538–542</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Magri V, Wagenlehner F, Perletti G, Schneider S, Marras E, Naber KG, Weidner W. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: Sexual function domain improves correlations. J Urol 2010;184:2339-2345</mixed-citation><mixed-citation xml:lang="en">Magri V, Wagenlehner F, Perletti G, Schneider S, Marras E, Naber KG, Weidner W. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: Sexual function domain improves correlations. J Urol 2010;184:2339-2345</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: A prospective study using UPOINT. Urology 2010;75:1249-1253</mixed-citation><mixed-citation xml:lang="en">Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: A prospective study using UPOINT. Urology 2010;75:1249-1253</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Magri V, Marras E, Restelli A, Wagenlehner FME, Perletti G. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exper Ther Med 2015;9:658-666</mixed-citation><mixed-citation xml:lang="en">Magri V, Marras E, Restelli A, Wagenlehner FME, Perletti G. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS  phenotyped patients. Exper Ther Med 2015;9:658-666</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
